Arkolith/Insider Trading/OYST/Form 4

Ozawa Clare

DirectorOyster Point Pharma, Inc. (OYST) · full profile →Form 4 · filed Jan 4, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
8
6 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 3, 2023Tender(U)415K——0
Jan 3, 2023Tender(U)2K——0
Jan 3, 2023Tender(U)1.0M——0
Jan 3, 2023Tender(U)2.2M——0
Jan 3, 2023Disposed to issuer(D)4K——0
Jan 3, 2023Disposed to issuer(D)11K——4K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 3, 2023Disposed to issuer(D)5K——0
Jan 3, 2023Disposed to issuer(D)5K——0

Transaction Codes

U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-001088) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML